Bavp, L.P.

Bavp, L.P. discloses dealings in 3 companies, chiefly Alimera Sciences Inc, SGX Pharmaceuticals, Inc. and Somaxon Pharmaceuticals, Inc. We count 57 filings; the first trade dates from 6 February 2006 and the latest from 21 April 2016.

In open-market terms, that means 3 purchases worth €5.9M on one side and 44 sales worth €2.9M on the other. Netting one side against the other leaves €3.0M of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2016 to date brings no purchases and 5 sales.

In size, the median ticket on the buying side is €2.5M.

The record was last updated on 22 April 2016 with an open-market sale (€179) in Alimera Sciences Inc. The latest purchase dates back some time: it was published 6,038 days ago, on 28 April 2010. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.